| Literature DB >> 35307965 |
Woo Sik Yu1, Jaeyong Shin2, Jung A Son1, Joonho Jung1, Seokjin Haam1.
Abstract
BACKGROUND: Textbook outcome (TO) has been introduced as a novel composite measure for lung cancer surgery. We investigated TO after lobectomy for early-stage non-small cell lung cancer (NSCLC) in a Korean tertiary hospital and its prognostic implications for overall survival and recurrence.Entities:
Keywords: carcinoma; healthcare; non-small cell lung cancer; quality indicators; thoracic surgery
Mesh:
Year: 2022 PMID: 35307965 PMCID: PMC9013659 DOI: 10.1111/1759-7714.14391
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.223
FIGURE 1Diagram of the study cohort selection process. AIS, adenocarcinoma in situ; MIA, microinvasive adenocarcinoma; NSCLC, non‐small cell lung cancer
Baseline characteristics of the achieved and failed textbook outcome groups
| Variable | All patients ( | Achieved TO ( | Failed TO ( |
|
|---|---|---|---|---|
| Age, years, mean ± SD | 63.6 ± 10.0 | 63.0 ± 9.9 | 64.9 ± 10.1 | 0.060 |
| Sex | <0.001 | |||
| Male | 273 (65.3%) | 163 (58.8%) | 110 (78.0%) | |
| Female | 145 (34.7%) | 114 (41.2%) | 31 (22.0%) | |
| Smoking | <0.001 | |||
| Non‐smoker | 163 (39.0%) | 126 (45.5%) | 37 (26.2%) | |
| Ex‐smoker | 128 (30.6%) | 82 (29.6%) | 46 (32.6%) | |
| Current smoker | 127 (30.4%) | 69 (24.9%) | 58 (41.1%) | |
| CCI | 0.018 | |||
| 0 | 197 (47.1%) | 143 (51.6%) | 54 (38.3%) | |
| 1 | 94 (22.5%) | 61 (22.0%) | 33 (23.4%) | |
| >2 | 127 (30.4%) | 73 (26.4%) | 54 (38.3%) | |
| FEV1, % predicted | 93.0 ± 13.8 | 93.5 ± 12.9 | 91.9 ± 15.3 | 0.271 |
| DLCO, % predicted | 77.0 ± 20.0 | 80.0 ± 19.3 | 71.0 ± 20.1 | <0.001 |
| Approach | 0.009 | |||
| VATS | 277 (66.3%) | 196 (70.8%) | 81 (57.4%) | |
| Thoracotomy | 141 (33.7%) | 81 (29.2%) | 60 (42.6%) | |
| Histology | <0.001 | |||
| Adeno | 286 (68.4%) | 208 (75.1%) | 78 (55.3%) | |
| Sq | 97 (23.2%) | 47 (17.0%) | 50 (35.5%) | |
| Other NSCLC | 35 (8.4%) | 22 (7.9%) | 13 (9.2%) | |
| Tumor size, cm | 3.1 ± 1.7 | 2.9 ± 1.5 | 3.4 ± 2.0 | 0.014 |
| Harvested LNs, | 24.0 ± 11.5 | 25.0 ± 11.0 | 22.0 ± 12.1 | 0.010 |
| Clinical stage | 0.221 | |||
| IA | 151 (34.1%) | 96 (34.7%) | 55 (39.0%) | |
| IB | 193 (43.2%) | 137 (49.5%) | 56 (39.7%) | |
| IIA | 10 (2.4%) | 5 (1.8%) | 5 (3.5%) | |
| IIB | 64 (15.3%) | 39 (14.1%) | 25 (17.7%) | |
| Pathological stage | 0.271 | |||
| IA | 129 (30.9%) | 88 (31.8%) | 41 (29.1%) | |
| IB | 145 (34.7%) | 104 (37.5%) | 41 (29.1%) | |
| IIA | 25 (6.0%) | 14 (5.1%) | 11 (7.8%) | |
| IIB | 59 (14.1%) | 33 (11.9%) | 26 (18.4%) | |
| IIIA | 52 (12.4%) | 33 (11.9%) | 19 (13.5%) | |
| IIIB | 8 (1.9%) | 5 (1.8%) | 3 (2.1%) |
Abbreviations: Adeno, adenocarcinoma; CCI, Charlson comorbidity index; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; LN, lymph node; SD, standard deviation; TO, textbook outcome; VATS, video‐assisted thoracoscopic surgery; NSCLC, non‐small cell lung cancer; Sq, squamous cell carcinoma.
FIGURE 2Diagram representing TO as composite measure of outcome parameters. TO, textbook outcome
Prevalence of events leading to textbook outcome failure
| Variable | Total patients ( |
|---|---|
| 30‐day or in‐hospital mortality | 6 (1.4%) |
| ICU readmission or prolonged stay | 16 (3.8%) |
| Readmission with 30 days | 14 (3.3%) |
| Prolonged hospital stay (≥14 days) | 53 (12.7%) |
| Prolonged air leakage (≥5 days) | 54 (12.9%) |
| Respiratory failure | 14 (3.3%) |
| Myocardial infarction | 2 (0.5%) |
| Thromboembolic event | 2 (0.5%) |
| Chylothorax | 4 (1.0%) |
| Empyema or BPF | 3 (0.7%) |
| Blood transfusion | 27 (6.5%) |
| Incomplete resection | 3 (0.7%) |
| Insufficient LN dissection | 34 (8.1%) |
Abbreviations: BPF, bronchopleural fistula; ICU, intensive care unit; LN, lymph node.
FIGURE 3Number of complications defining TO failure among patients who failed TO achieve TO. TO, textbook outcome
Predicted factors for achievement of textbook outcome according to the logistic regression model
| Variable | Full model | Stepwise model | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Age | 0.997 | 0.970–1.025 | 0.836 | |||
| Male (vs. female) | 2.148 | 1.050–4.405 | 0.036 | 2.162 | 1.350–3.526 | 0.002 |
| Smoking | ||||||
| Non‐smoker | Reference | |||||
| Ex‐smoker | 0.711 | 0.325–1.559 | 0.391 | |||
| Current smoker | 1.178 | 0.551–2.523 | 0.672 | |||
| CCI ≥ 2 | 1.582 | 0.985–2.538 | 0.057 | 1.501 | 0.949–2.365 | 0.081 |
| Preop FEV1, % predicted | 0.999 | 0.982–1.016 | 0.882 | |||
| Preop DLCO, % predicted | 0.986 | 0.972–1.000 | 0.047 | 0.982 | 0.971–0.993 | 0.002 |
| VATS (vs. open) | 0.727 | 0.451–1.178 | 0.193 | 0.650 | 0.416–1.017 | 0.058 |
| Histology | ||||||
| Adeno | Reference | |||||
| Sq | 1.618 | 0.919–2.846 | 0.095 | |||
| Other NSCLC | 1.141 | 0.511–2.455 | 0.741 | |||
| Tumor size, cm | 1.121 | 0.963–1.311 | 0.144 | |||
| Clinical stage | ||||||
| I | Reference | |||||
| II | 0.699 | 0.363–1.313 | 0.273 | |||
Abbreviations: Adeno, adenocarcinoma; CCI, Charlson comorbidity index; CI, confidence interval; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; NSCL, non‐small cell lung cancer; OR, odds ratio; Sq, squamous cell carcinoma; VATS, video‐assisted thoracoscopic surgery.
Baseline characteristics of the achieved and failed textbook outcome groups in the matched cohort
| Achieved TO ( | Failed TO ( | SMD | |
|---|---|---|---|
| Age, years, mean ± SD | 63.5 ± 9.6 | 64.4 ± 10.3 | 0.096 |
| Male sex | 100 (78.1) | 99 (77.3) | 0.019 |
| Smoking | 0.055 | ||
| Non‐smoker | 36 (28.1) | 36 (28.1) | |
| Ex‐smoker | 41 (32.0) | 44 (34.4) | |
| Current smoker | 51 (39.8) | 48 (37.5) | |
| CCI | 0.073 | ||
| 0 | 50 (39.1) | 52 (40.6) | |
| 1 | 33 (25.8) | 29 (22.7) | |
| ≥2 | 45 (35.2) | 47 (36.7) | |
| Preop FEV1, % predicted | 95.52 (13.03) | 92.26 (14.67) | 0.019 |
| Preop DLCO, % predicted | 74.93 (18.20) | 72.90 (19.46) | 0.108 |
| VATS | 79 (61.7) | 77 (60.2) | 0.032 |
| Histology | 0.027 | ||
| Adeno | 75 (58.6) | 76 (59.4) | |
| Sq | 40 (31.2) | 40 (31.2) | |
| Other NSCLC | 13 (10.2) | 12 (9.4) | |
| Tumor size, cm | 3.2 ± 1.5 | 3.2 ± 1.7 | 0.013 |
| Clinical stage | 0.163 | ||
| IA | 47 (36.7) | 50 (39.1) | |
| IB | 57 (44.5) | 54 (42.2) | |
| IIA | 5 (3.9) | 2 (1.6) | |
| IIB | 19 (14.8) | 22 (17.2) | |
| Pathological stage | 0.144 | ||
| IA | 40 (31.2) | 38 (29.7) | |
| IB | 41 (32.0) | 40 (31.2) | |
| IIA | 11 (8.6) | 10 (7.8) | |
| IIB | 16 (12.5) | 21 (16.4) | |
| IIIA | 15 (11.7) | 16 (12.5) | |
| IIIB | 5 (3.9) | 3 (2.3) |
Abbreviations: Adeno, adenocarcinoma; CCI, Charlson comorbidity index; DLCO, diffusing capacity for carbon monoxide; FEV1, forced expiratory volume in 1 s; NSCL, non‐small cell lung cancer; SD, standard deviation; SMD, standardized mean difference; VATS, video‐assisted thoracoscopic surgery; Sq, squamous cell carcinoma.
FIGURE 4Financial implications of textbook outcome (TO) in unmatched and matched cohorts. (a) Unmatched cohorts. (b) Matched cohort
FIGURE 5Overall survival in the unadjusted (a) and matched cohorts (b). Cumulative incidence of recurrence in the unadjusted (c) and matched cohorts (d). TO, textbook outcome